Source: Eur Respir Rev 2007; 16: 85-87
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
-M. Beeh K.. Which patients should be treated with anti-IgE?. Eur Respir Rev 2007; 16: 85-87

Member's Comments

No comment yet.

Related content which might interest you: Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007 Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005 10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab. Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment? Source: Annual Congress 2013 –Treatment of asthma Year: 2013 ‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study Source: Annual Congress 2011 - Asthma management and response Year: 2011 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Cost analysis for patients with severe asthma receiving omalizumab treatment Source: International Congress 2019 – Clinical aspects of airway diseases Year: 2019 Salmeterol treatment improves corticosteroid responsivness in patients with corticosteroid-insensitive severe asthma Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population Year: 2005 Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability Source: International Congress 2014 – Markers Year: 2014 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 The efficacy of omalizumab in severe in asthma after treatment withdrawal Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009